Predicta Biosciences’ Post

Biofourmis Chief Operating Officer Jaydev Thakkar will be in Basel, Switzerland on June 26 for the 7th annual Digital Biomarkers in Clinical Trials Summit to participate in a panel discussion on digital biomarkers in Oncology. Thakkar will join leaders from Roche, Johnson & Johnson Innovative Medicine, and Evinova to go beyond the more established field of measuring activity levels and motor symptoms with digital health tools, to discuss what additional measurement approaches are being explored within Oncology. Heading to Basel? Send us a message! We’d love to share more about how our pharma partners are leveraging our enterprise platform and device ecosystem to advance cancer research and development. https://lnkd.in/drySvksT I #DigitalBiomarkers #Oncology #DigitalClinicalTrials #ClinicalTrials #DigitalHealth

🔬 Ever wondered how working at an Innovation Space may enhance your ability to collaborate and fast-forward your next groundbreaking innovation?   Basel-based Engimmune Therapeutics and the Swiss innovation center CSEM, housed at the Switzerland Innovation Park Basel Area - Main Campus HQ, discuss in an interview how and why they started to work together to advance cancer treatment. Watch it below 👇 Engimmune Therapeutics, also part of BaseLaunch's portfolio, is a spin-off from ETH Zürich on a quest to revolutionize cancer treatment with soluble T cell receptors (TCR). CSEM, a landmark of Swiss technological innovation, is on a mission to bridge the gap between research and industry. The synergy between Engimmune’s TCR technology and CSEM’s microfluidic prowess has set the stage for a leap in cancer therapy development. By encapsulating individual TCR tests in microscopic droplets, cross-contamination is eliminated, ensuring precise and reliable results. This innovation dramatically accelerates the screening process, turning what used to take months into a matter of weeks, and significantly increasing the number of TCR candidates that can be de-risked in preparation for clinical trials. Read the full article right here: https://lnkd.in/eiGCKE3Y Rodrigo Vazquez-Lombardi | Felix K. #innovation #startups #collaboration #healthcare #lifescience

Great news! Our CEO, Sean A. MacDonald, will be participating in the highly anticipated LSX World Congress, taking place this April 29-30 in London, UK! Don't miss Sean'presentation on Monday as he will share Domain Therapeutics' exciting advancements in precision medicine for cancer treatment. At Domain, we're not just pioneering innovative therapies. We're redefining what's possible in the fight against cancer. Through our unwavering commitment to leveraging G Protein-Coupled Receptors (GPCRs) in immuno-oncology, we unlock new possibilities to beat resistance and defeat cancer. If you'll be participating in this premier gathering of industry leaders and investors, don't miss this valuable opportunity to connect with Sean and discuss Domain Therapeutics' very hot targets and our innovative approach to cancer therapy. Let's ignite conversations, forge partnerships, and drive global innovation in healthcare together. See you at LSX - partnering for Life Science eXecutives World Congress! #PrecisionMedicine #Immunooncology #Biotech #Innovation #Fundraising

🚀 Excited to share that I’ll be representing Epigene Labs at the J.P. Morgan Healthcare Conference 2025! From January 13–16, our VP of Business Development, Kevin Cho, and I will be in San Francisco for this premier global gathering of biopharma leaders and innovators. 🌍💊 🔍 Why meet with us? At Epigene Labs, we’re unlocking insights for faster precision #oncology breakthroughs. Our mCUBE platform combines #AI and advanced #bioinformatics to transform fragmented cancer research data into cohesive, high-resolution disease atlases. Here’s what makes mCUBE stand out: 🌐 Multi-source: Access to 90,000+ patient sample profiles from 950+ datasets 🌐 Multi-omic: Integration of multiple layers of genomic information 🌐 Multi-cancer: Coverage of 30+ cancer types By streamlining scattered omic datasets into actionable insights, we help compress R&D timelines from months to days—potentially increasing success rates by up to 3X. 📩 Let’s connect to supercharge your precision oncology programs and gain a smarter, data-driven edge in #cancer research and drug development. Together, we can drive breakthroughs faster. 💡

At Provectus Therapeutics, we are redefining the landscape of cancer treatment through Predictive Precision & Innovation. Our mission is to leverage advanced technologies, including AI and precision medicine, to empower patients with personalized cancer treatment by identifying tumor resistance before it begins. Join us at our upcoming Investor Meeting to discover how we together can shape a better future through our cutting-edge technology and vision. 📅 Date: 15/11/2024 (Hong Kong Time Zone - GMT+8) 🕒 Time: 1500 - 1600 📍 Location: Online Join us to see how we are shaping the future of oncology. This is your chance to invest in a company that not only promises but delivers innovation with a profound impact on healthcare. Registration Link : https://lnkd.in/gUi3k4AX Together, let's pioneer a future where cancer is no longer a life sentence, but a challenge we conquer with precision, innovation, and care. #CancerCare #Innovation #PrecisionMedicine #Healthcare #AI #InvestorMeeting

𝐊𝐢𝐯𝐮 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐣𝐮𝐬𝐭 𝐫𝐚𝐢𝐬𝐞𝐝 $92𝐌 𝐭𝐨 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬! 𝐖𝐡𝐢𝐥𝐞 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐃𝐂𝐬 𝐟𝐚𝐜𝐞 𝐥𝐢𝐦𝐢𝐭𝐬 𝐝𝐮𝐞 𝐭𝐨 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬, 𝐊𝐢𝐯𝐮’𝐬 𝐜𝐮𝐭𝐭𝐢𝐧𝐠-𝐞𝐝𝐠𝐞 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐩𝐫𝐨𝐦𝐢𝐬𝐞𝐬 𝐬𝐚𝐟𝐞𝐫, 𝐦𝐨𝐫𝐞 𝐩𝐫𝐞𝐜𝐢𝐬𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐞𝐱𝐩𝐚𝐧𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬. Using Synaffix BV’s GlycoConnect™ technology, Kivu’s ADCS offer unparalleled stability and reduce off-target side effects, opening new possibilities in oncology. With support from top investors like Novo Holdings, HealthCap, and Red Tree Venture Capital, Kivu Bioscience is set to begin Phase 1 trials in 2025. As COO Mohit Trikha , Ph.D., shares, They are excited to develop ADC therapies that are both more effective and safer for cancer patients. Do you believe antibody-drug conjugates could be the future of oncology? Helen Y. Chen, Neda Emami, Robert Salcedo, Jeff Fairman, Emmanouela Petsolari, Fabian Hansen, Lucia Beviglia, Clare Matschullat, Kristofer Patel Christina Lopes, Alexey Bazarov, Jay Chia, Crystal Cassidy, Joon S. Park #BiotechInnovation #CancerResearch #ADCTherapy #LifeSciences ----- 𝑳𝒆𝒂𝒓𝒏 𝒎𝒐𝒓𝒆 𝒂𝒃𝒐𝒖𝒕 𝒖𝒔 ➡ https://lnkd.in/ed_mKpkF

Pioneering Therapeutic Innovation: Highlights from the First hashtag #THRPTX Summit in Paris-Saclay After months of preparation, we're thrilled to reflect on this groundbreaking symposium that brought together today over 200 international experts, decision-makers, and healthcare professionals at our R&D Institute in Paris-Saclay. 🌍 Global Collaboration: THRPTX united brilliant minds from across the globe, fostering dialogue and collaboration that transcends borders in the pursuit of therapeutic innovation. 🧬 Scientific Excellence: Under the patronage of Nobel Laureate Prof. William G. Kaelin Jr., we explored cutting-edge innovations in oncology, from diagnosis to post-cancer care, and the profound impact of medical advancements on society. 🤝 Cross-disciplinary Synergy: The summit exemplified the power of cross-functionality, leveraging the Paris-Saclay ecosystem to accelerate R&D effectiveness and drive forward-thinking solutions in healthcare. 🔬 Patient-Centric Innovation: Discussions centered on patient needs, highlighting our commitment to developing therapies that positively impact patients' lives and their families. 💡 Future-Focused Dialogue: From AI and digital tools to the role of health data, we delved into the future of medical practices and society's expectations for health innovation. A special moment was the engaging exchange between Prof. Kaelin and Selena Bouffette, a Servier doctoral student representing our SHINEDocs community – bridging generations of scientific talent. Heartfelt thanks to Olivier Laureau, Claude Bertrand, and all the speakers, participants, and organizers who made THRPTX a resounding success. This summit reaffirms our position as a key player in global health innovation. As we look ahead, we're excited to continue driving therapeutic breakthroughs that will shape the future of healthcare and science. #TherapeuticInnovation #oncology #AI #MovedByYou #WeAreServier

We are immensely excited to announce our official launch as a company, with $150M Series A financing. Clasp Therapeutics aims to expand the reach of immuno-oncology by creating novel precision medicines to help people with cancer live longer and healthier lives.   We are developing unique antibody-like T cell engagers that can be matched to an individual’s immune system and their specific tumor’s genetics. By targeting the truncal driver mutations that lie at the root of cancer growth, we hope to give every patient the opportunity to respond to treatment.   Clasp was born out of scientific advancements made by its founders at The Johns Hopkins University, including Bert Vogelstein and Drew Pardoll. The company is helmed by industry veteran Robert Ross. The financing was led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, with participation from Cure Ventures, Vivo Capital, Alexandria Real Estate Equities, Inc., Blackbird BioVentures, BrightEdge - American Cancer Society , and Pictet Group.   The goal of our approach is to create a personalized, but off-the-shelf therapy, that enlists all types of a patient’s T cells to eradicate tumor cells with absolute specificity.   For more information on today’s launch announcement, please see our press release: https://lnkd.in/eCGwcbDv You can learn more about Clasp by visiting our website here: www.clasptx.com   #patients #cancer #immunooncology #TCellEngagers #oncology #precisionmedicine  

I want to share an interesting article of Francesco Hofmann our Head of Research and Development explaining how we aim to accelerate the development of targeted cancer therapies through strategic partnerships. Why partnerships? They allow us to tap into specialized skills and diverse perspectives, essential for a mid-sized company like ours to bring new therapeutic options to patients on unmet medical needs 🔬 At the pre-clinical stage, we collaborate with experts like Vernalis for molecule creation. 🤝 In clinical development, we co-develop with companies like Scorpion Therapeutics for lung cancer treatments. 🏢 Some partnerships lead to acquisitions, such as our recent acquisition of Vertical Bio. 💪 #Oncology #Partnerships #Innovation #Healthcare #ResearchAndDevelopment #PrecisionOncology #PierreFabre

AIM-HI congratulates March Biosciences, led by CEO & Co-Founder Sarah Hein, Ph.D., the First Prize Winner with Distinction of our 2023 AIM-HI Women's Venture Competition, for closing a $28.4 million oversubscribed Series A financing. March Bio is an emerging clinical-stage #biotech company committed to combating challenging cancers and other diseases. Funds will support Phase 2 development of March Bio’s lead CD5 CAR-T therapy, MB-105, for T-cell lymphoma and pipeline candidates. Read More: https://bit.ly/4f10obZ The AIM-HI Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology startups. The competition’s review committees provided assessments and recommendations for recognizing the Women’s Venture Competition winners based on scientific and clinical merits and business impact for #cancer patients. Support Our Mission: https://bit.ly/47VzZJE #AIMHIaccelerator #WomenEmpowerment #DriveCuresForward Sujuan Ba Dimitra Georganopoulou Rose Wang Matt Tremblay, Ph.D. National Foundation for Cancer Research (NFCR) OncoDaily